These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1135 related items for PubMed ID: 9601876

  • 21. Longitudinal fluctuation of antibodies to extractable nuclear antigens in systemic lupus erythematosus.
    Faria AC, Barcellos KS, Andrade LE.
    J Rheumatol; 2005 Jul; 32(7):1267-72. PubMed ID: 15996063
    [Abstract] [Full Text] [Related]

  • 22. Survival impact of autoantibodies in systemic lupus erythematosus.
    Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcón GS.
    J Rheumatol; 1994 Feb; 21(2):224-8. PubMed ID: 8182629
    [Abstract] [Full Text] [Related]

  • 23. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
    Magalhães MB, da Silva LM, Voltarelli JC, Donadi EA, Louzada-Junior P.
    Scand J Rheumatol; 2007 Feb; 36(6):442-7. PubMed ID: 18092265
    [Abstract] [Full Text] [Related]

  • 24. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
    Vlachoyiannopoulos PG, Toya SP, Katsifis G, Zintzaras E, Tzioufas AG, Moutsopoulos HM.
    J Rheumatol; 2008 Sep; 35(9):1768-75. PubMed ID: 18634157
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases.
    Salonen EM, Miettinen A, Walle TK, Koskenmies S, Kere J, Julkunen H.
    Ann Rheum Dis; 2004 Oct; 63(10):1250-4. PubMed ID: 15361381
    [Abstract] [Full Text] [Related]

  • 27. Development of autoantibodies before the clinical onset of systemic lupus erythematosus.
    Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB.
    N Engl J Med; 2003 Oct 16; 349(16):1526-33. PubMed ID: 14561795
    [Abstract] [Full Text] [Related]

  • 28. Quantitative radioligand assays using de novo-synthesized recombinant autoantigens in connective tissue diseases: new tools to approach the pathogenic significance of anti-RNP antibodies in rheumatic diseases.
    Yamamoto AM, Amoura Z, Johannet C, Jeronimo AL, Campos H, Koutouzov S, Piette JC, Bach JF.
    Arthritis Rheum; 2000 Mar 16; 43(3):689-98. PubMed ID: 10728764
    [Abstract] [Full Text] [Related]

  • 29. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
    Morel J, Roubille C, Planelles L, Rocha C, Fernandez L, Lukas C, Hahne M, Combe B.
    Ann Rheum Dis; 2009 Jun 16; 68(6):997-1002. PubMed ID: 18676986
    [Abstract] [Full Text] [Related]

  • 30. [Hematological abnormalities in systemic lupus erythematosus and clinical significance thereof: comparative analysis of 236 cases].
    Chen JL, Huang XM, Zeng XJ, Wang Y, Zhou MX, Ma YH, Li RS, Shen T.
    Zhonghua Yi Xue Za Zhi; 2007 May 22; 87(19):1330-3. PubMed ID: 17727778
    [Abstract] [Full Text] [Related]

  • 31. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK.
    Arthritis Rheum; 2005 May 22; 52(5):1491-503. PubMed ID: 15880830
    [Abstract] [Full Text] [Related]

  • 32. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.
    Zandman-Goddard G, Blank M, Langevitz P, Slutsky L, Pras M, Levy Y, Shovman O, Witte T, Doria A, Rovensky J, Shoenfeld Y.
    Ann Rheum Dis; 2005 Dec 22; 64(12):1698-702. PubMed ID: 16014675
    [Abstract] [Full Text] [Related]

  • 33. [A novel method for screening anti-inner ear autoantibody in patients with autoimmune diseases].
    Zou J, Bi A, Wu X, Yang W, Li Z.
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2000 Apr 22; 35(2):113-6. PubMed ID: 12768666
    [Abstract] [Full Text] [Related]

  • 34. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus.
    Hoffman IE, Peene I, Meheus L, Huizinga TW, Cebecauer L, Isenberg D, De Bosschere K, Hulstaert F, Veys EM, De Keyser F.
    Ann Rheum Dis; 2004 Sep 22; 63(9):1155-8. PubMed ID: 15308527
    [Abstract] [Full Text] [Related]

  • 35. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations.
    Vilá LM, Alarcón GS, McGwin G, Friedman AW, Baethge BA, Bastian HM, Fessler BJ, Reveille JD, LUMINA Study Group.
    Rheumatology (Oxford); 2004 Mar 22; 43(3):358-63. PubMed ID: 14623949
    [Abstract] [Full Text] [Related]

  • 36. [The importance of determination of interleukin-10 in the blood of patients with systemic lupus erythematosus].
    Scudla V, Horák P, Faltýnek L, Pospísil Z, Budíková M, Hermanová Z.
    Cas Lek Cesk; 1998 Jan 26; 137(2):44-7. PubMed ID: 9511265
    [Abstract] [Full Text] [Related]

  • 37. Correlation between the levels of antinuclear antibodies, anti-DNA antibodies, and complement in systemic lupus erythematosus.
    Nguyen CP, Cao VV, Fehér J, Gergely P.
    Acta Med Hung; 1988 Jan 26; 45(2):145-59. PubMed ID: 3266790
    [Abstract] [Full Text] [Related]

  • 38. Reduced anti-TNFalpha autoantibody levels coincide with flare in systemic lupus erythematosus.
    Sjöwall C, Ernerudh J, Bengtsson AA, Sturfelt G, Skogh T.
    J Autoimmun; 2004 Jun 26; 22(4):315-23. PubMed ID: 15120755
    [Abstract] [Full Text] [Related]

  • 39. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q.
    Mok CC, Birmingham DJ, Ho LY, Hebert LA, Song H, Rovin BH.
    Lupus; 2012 Jan 26; 21(1):36-42. PubMed ID: 21993384
    [Abstract] [Full Text] [Related]

  • 40. Clinical and serological heterogeneity in patients with anticentromere antibodies.
    Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y.
    J Rheumatol; 2005 Aug 26; 32(8):1488-94. PubMed ID: 16078324
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.